As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks ...

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ...

The stress axis that has been most extensively studied in relation to stress is unquestionably the hypothalamic pituitary ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...

Clene will join APST Research to explore how CNM-Au8 affects NfL levels in ALS patients treated in expanded access programs.

Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET. Company Participants. Katie Hogan - Senior Director-Corporate Communications and Investo ...

Five years later, and in the face of a potentially changing healthcare landscape again, Dr. Lynch is ever committed and steadfast in his vision for the NCI-designated cancer center. He recently shared ...